Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Total Non-Current Liabilities: 2009-2024

Historic Total Non-Current Liabilities for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to $46.7 million.

  • Cumberland Pharmaceuticals' Total Non-Current Liabilities fell 26.07% to $34.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.1 million, marking a year-over-year decrease of 26.07%. This contributed to the annual value of $46.7 million for FY2024, which is 1.47% up from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $46.7 million for FY2024, which was up 1.47% from $46.1 million recorded in FY2023.
  • In the past 5 years, Cumberland Pharmaceuticals' Total Non-Current Liabilities registered a high of $49.4 million during FY2022, and its lowest value of $34.4 million during FY2021.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $46.7 million (2024), whereas its average is $47.4 million.
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Total Non-Current Liabilities dropped by 17.63% in 2021, and later surged by 43.64% in 2022.
  • Over the past 5 years, Cumberland Pharmaceuticals' Total Non-Current Liabilities (Yearly) stood at $41.7 million in 2020, then fell by 17.63% to $34.4 million in 2021, then spiked by 43.64% to $49.4 million in 2022, then dropped by 6.69% to $46.1 million in 2023, then rose by 1.47% to $46.7 million in 2024.